AstraZeneca stock fell sharply on Monday as investors reacted negatively to reports that the British pharmaceutical company held merger discussions with Bristol Myers Squibb. On the other hand, BMY stock rose in premarket trading as the potential transaction generated optimism among Bristol Myers shareholders.
Shares of AstraZeneca declined 4.7%, which made the company the second-worst performer on the FTSE 100 at the time. Meanwhile, Bristol Myers Squibb shares climbed by more than 4% in US premarket trading.
AstraZeneca stock price (Source: Google Finance)
The contrasting stock performances suggest investors believe Bristol Myers could benefit more from the potential deal, while AstraZeneca shareholders are concerned about the strategic and financial implications of such a large acquisition.
BMY stock price (Source: Google Finance)
Proposed Merger Could Create a $400 Billion Drugmaker
AstraZeneca and Bristol Myers Squibb reportedly held discussions about a possible combination, according to a person familiar with the matter. However, no formal agreement has been announced, and it is still unclear whether the talks will actually lead to a transaction.
Based on their market values at the end of Friday’s trading session, the companies had a combined market capitalization of nearly $400 billion. AstraZeneca was valued at approximately $264.11 billion, while Bristol Myers had a market value of around $133.41 billion.
Keeping this in mind, a completed merger could create the world’s fourth-largest pharmaceutical company by market capitalization and the largest by revenue.
AstraZeneca Shareholders Question Strategic Benefits
The decline in AstraZeneca stock could be due to concerns that the company has little need for a transformative acquisition of this size. AstraZeneca has already been expanding in the United States and investing heavily in its pipeline, manufacturing capacity and commercial operations.
Lucy Coutts, investment director at AstraZeneca shareholder JM Finn, said the clearest potential advantage would be accelerating AstraZeneca’s US presence and sales. However, she argued that the company was already pursuing this strategy at a pace and cost that benefited shareholders.
Markus Manns, a portfolio manager at AstraZeneca shareholder Union Investment, was more direct by saying that a combination with Bristol Myers did not appear to make strategic or financial sense.
Investors may also be concerned about the costs, integration risks and potential disruption associated with combining two enormous pharmaceutical businesses. Mega-mergers can offer financial efficiencies and broader product portfolios, but they can also introduce a lot of debt, regulatory scrutiny and execution challenges.
Why BMY Stock Rose
The rise in BMY stock indicates that Bristol Myers investors may see the reported talks as an opportunity for shareholders to receive a takeover premium or gain exposure to AstraZeneca’s stronger growth prospects.
Bristol Myers has faced some pressure from upcoming patent expirations and competition affecting some of its major medicines. A deal with AstraZeneca could give the combined business a more diversified pipeline and a larger international commercial footprint.
